Table 2.
GRADE assessment for outcomes reported in randomized controlled trials (RCTs) on PRP vs control for total knee arthroplasty.
| Outcomes | No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | No. of patients |
Relative effect (95% CI) | Certaintya | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PRP | Control | ||||||||||
| Pain at POD 1 | 3 | RCT | No | Seriousc | No | No | No | 80 | 81 | MD −0.47 (−1.31, 0.38) | ⊕⊕⊕○ Moderate |
| Pain at POD 2 | 3 | RCT | No | Seriousc | No | No | No | 80 | 81 | MD −0.63 (−1.38, 0.13) | ⊕⊕⊕○ Moderate |
| Pain at 3 weeks | 2 | RCT | No | No | No | No | No | 40 | 41 | MD −0.92 (−1.25, −0.60) | ⊕⊕⊕⊕ High |
| Pain at 2 months | 2 | RCT | No | No | No | No | No | 40 | 41 | MD −0.93 (−1.24, −0.63) | ⊕⊕⊕⊕ High |
| ROM at POD 2 | 3 | RCT | No | No | No | No | Seriousd | 110 | 112 | MD 1.90 (−1.09, 4.87) | ⊕⊕⊕○ Moderate |
| ROM at POD 5 | 2 | RCT | No | No | No | No | No | 27 | 34 | MD 3.16 (−0.73, 7.06) | ⊕⊕⊕⊕ High |
| ROM at 1 week | 2 | RCT | Seriousb | No | No | No | No | 129 | 226 | MD −1.60 (−4.62, 1.42) | ⊕⊕⊕○ Moderate |
| ROM at 2 weeks | 2 | RCT | Seriousb | No | No | No | Seriousd | 159 | 258 | MD −0.88 (−0.37, 1.94) | ⊕⊕○○ Low |
| ROM at 6 weeks | 2 | RCT | No | Seriousc | No | No | Seriousd | 70 | 72 | MD 3.88 (−5.23, 12.98) | ⊕⊕○○ Low |
| WOMAC score at 6 weeks | 2 | RCT | No | Seriousc | No | No | Seriousd | 57 | 66 | MD −2.37 (−9.78, 5.04) | ⊕⊕○○ Low |
| WOMAC score at 2 months | 2 | RCT | No | Seriousc | No | No | No | 40 | 41 | MD 2.90 (−3.97, 9.76) | ⊕⊕⊕○ Moderate |
| WOMAC score at 3 months | 2 | RCT | No | Seriousc | No | No | No | 57 | 66 | MD −0.71 (−8.51, 7.08) | ⊕⊕⊕○ Moderate |
| WOMAC score at 6 months | 2 | RCT | No | No | No | No | No | 27 | 35 | MD −0.69 (−1.65, 0.28) | ⊕⊕⊕⊕ High |
| Length at hospital stay | 3 | RCT | No | Seriousc | No | No | No | 67 | 74 | MD −1.27 (−2.90, 0.35) | ⊕⊕⊕○ Moderate |
| Hemoglobin drop | 3 | RCT | Seriousb | No | No | No | Seriousd | 179 | 279 | MD −0.21 (−0.40, −0.02) | ⊕⊕○○ Low |
| Total blood loss | 3 | RCT | Seriousb | No | No | No | No | 169 | 266 | MD −56.50 (−131.13, 18.12) | ⊕⊕⊕○ Moderate |
| Wound infection | 4 | RCT | No | No | No | No | Seriousd | 110 | 113 | RR 1.02 (0.93, 1.11) | ⊕⊕⊕○ Moderate |
GRADE Working Group grades of evidence: High quality = we are very confident that the true effect lies close to that of the estimate of the effect.; Moderate quality = we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; Low quality = our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; Very low quality = we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
Downgraded one level for concerns with performance bias.
Downgraded one level for I2 > 50%.
Downgraded one level for publication bias.